New Zealand markets open in 5 hours 48 minutes

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
8.54-0.05 (-0.58%)
As of 10:12AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close8.59
Open8.52
Bid8.56 x 4000
Ask8.55 x 1100
Day's range8.49 - 8.59
52-week range8.24 - 13.30
Volume969,754
Avg. volume8,884,042
Market cap9.456B
Beta (5Y monthly)1.28
PE ratio (TTM)12.94
EPS (TTM)0.66
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est11.39
  • GlobeNewswire

    Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

    Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva will receive an exclusive license to bring firibastat to its home market, Israel PARIS, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension, has today announced the signing of an exclusive

  • Business Wire

    Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement

    TEL AVIV, Israel, November 10, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") and that it is increasing the combined aggregate purchase price (exclusive of accrued and unpaid interest) (the "Total Maximum Amount") from $3,500,000,000 to $4,000,000,000 for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:

  • Motley Fool

    4 No-Brainer Buffett Stocks to Buy With $500 in November

    Perhaps no investor has demonstrated how powerful an ally time can be than Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett. Since taking over as CEO in 1965, the Oracle of Omaha has led Berkshire to an average annual return of 20% on the nose, through 2020. This might not sound like much nominally, but when examined in aggregate through 2021's year-to-date gains, it works out to an increase in Berkshire's Class A shares (BRK.A) of almost 3,500,000%.